Keith L. Davis

12.4k total citations
238 papers, 9.2k citations indexed

About

Keith L. Davis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Psychiatry and Mental health. According to data from OpenAlex, Keith L. Davis has authored 238 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 36 papers in Psychiatry and Mental health. Recurrent topics in Keith L. Davis's work include Schizophrenia research and treatment (17 papers), Lung Cancer Treatments and Mutations (16 papers) and Advanced Breast Cancer Therapies (14 papers). Keith L. Davis is often cited by papers focused on Schizophrenia research and treatment (17 papers), Lung Cancer Treatments and Mutations (16 papers) and Advanced Breast Cancer Therapies (14 papers). Keith L. Davis collaborates with scholars based in United States, United Kingdom and Germany. Keith L. Davis's co-authors include Vahram Haroutunian, L.J. Siever, Sean D. Candrilli, Juliana Meyers, Richard C. Mohs, Pavel Katsel, Belinda Davis, Peter Powchik, Heather M. Edin and Aleksander A. Mathé and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Keith L. Davis

229 papers receiving 8.7k citations

Peers

Countries citing papers authored by Keith L. Davis

Since Specialization

Citations

This map shows the geographic impact of Keith L. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith L. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith L. Davis more than expected).

Fields of papers citing papers by Keith L. Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith L. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith L. Davis. The network helps show where Keith L. Davis may publish in the future.

Co-authorship network of co-authors of Keith L. Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Keith L. Davis. A scholar is included among the top collaborators of Keith L. Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith L. Davis. Keith L. Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	EP.08.22 Treatment Patterns and Clinical Outcomes in South Korean Patients With Unresectable Stage III EGFRm NSCLC Undergoing CRT 2025 ·Journal of Thoracic Oncology ·(unknown), (unknown), S-W. Kim, Keith L. Davis, (unknown), (unknown), Yong-Jin Kim	0
2	Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2− advanced breast cancer in Europe 2025 ·Breast Cancer Research and Treatment ·Olga Oikonomidou, Mark Beresford, (unknown), (unknown), Rohan Parikh, (unknown), Connie Chen, Justin Doan, Benjamin Li, (unknown), (unknown), María I. Jiménez, Keith L. Davis, Edward Broughton	0
3	Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study 2024 ·Future Oncology ·Muhammad Furqan, Siddharth Karanth, RK Goyal, Beilei Cai, (unknown), Keith L. Davis, (unknown), (unknown)	1
4	Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma 2024 ·The Oncologist ·Jeffrey S. Weber, Waqas Haque, Svetomir N. Markovic, April K.S. Salama, Inderjit Mehmi, Ryan J. Sullivan, Yana G. Najjar, Alexander C. J. van Akkooi, Alexander M Menzies, Georgina V Long, (unknown), (unknown), (unknown), Keith L. Davis, Siddharth Karanth, (unknown), (unknown)	0
5	Patient Characteristics, Treatment Patterns, and Health Outcomes in a Real-World Population of Patients with Myelofibrosis Treated with Fedratinib 2023 ·Blood ·Francesco Passamonti, Rohan Parikh, (unknown), (unknown), (unknown), (unknown), (unknown), Keith L. Davis, (unknown)	1
6	Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib 2023 ·Future Oncology ·Paul K. Paik, RK Goyal, Beilei Cai, Mark Price, Keith L. Davis, (unknown), (unknown), (unknown)	10
7	1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma 2023 ·Annals of Oncology ·Jeffrey S. Weber, Waqar Haque, Svetomir N. Markovic, April K.S. Salama, Inderjit Mehmi, Ryan J. Sullivan, Yana G. Najjar, Alexander C. J. van Akkooi, Alexander M. Menzies, Georgina V. Long, Alison Taylor, John B.A.G. Haanen, (unknown), Keith L. Davis, Siddharth Karanth, Riddhishkumar Shah, (unknown), (unknown)	1
8	Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma 2022 ·Blood Advances ·Gilles Salles, Stephen J. Schuster, Martin Dreyling, (unknown), John Kuruvilla, Piers Patten, Bastian von Tresckow, Sonali M. Smith, Ana Jiménez Ubieto, Keith L. Davis, (unknown), Jufen Chu, Jie Zhang, Chiara Lobetti Bodoni, Catherine Thiéblemont, Nathan Fowler, Michael Dickinson, Joaquín Martínez‐López, Yucai Wang, Brian K. Link	26
9	Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real‐world evidence from the medicare population 2021 ·Cancer Medicine ·RK Goyal, Saurabh Nagar, Shaum Kabadi, (unknown), Keith L. Davis, James A. Kaye	18
10	European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review 2021 ·Drugs - Real World Outcomes ·Riyaz Shah, Nicolas Girard, Saurabh Nagar, Frank Griesinger, (unknown), Keith L. Davis, Parisa Karimi, W. Sawyer, Ning Yu, Aliki Taylor, Josephine Feliciano	9
11	Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma 2021 ·Leukemia & lymphoma ·RK Goyal, Preetesh Jain, Saurabh Nagar, (unknown), Shaum Kabadi, Keith L. Davis, James A. Kaye, Xianglin L. Du, Michael Wang	5
12	Clinical implications of prolonged hyperglycaemia before basal insulin initiation in type 2 diabetes patients: An electronic medical record database analysis 2019 ·Endocrinology Diabetes & Metabolism ·D. Raccah, Bruno Guerci, Mayank Ajmera, Keith L. Davis, Juliana Meyers, (unknown), Alka Shaunik, Lawrence Blonde	2
13	Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States 2019 ·Cancer Medicine ·Shaum Kabadi, RK Goyal, Saurabh Nagar, James A. Kaye, Keith L. Davis	31
14	Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2− metastatic breast cancer 2019 ·Current Medical Research and Opinion ·RK Goyal, Gebra Cuyún Carter, Saurabh Nagar, Emily Nash Smyth, Gregory L. Price, (unknown), Li Li, Keith L. Davis, James A. Kaye	10
15	Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer 2018 ·Lung Cancer ·Leora Horn, Joshua Bauml, Patrick M. Forde, Keith L. Davis, Nathaniel J. Myall, Medha Sasané, Anand A. Dalal, (unknown), Antoinette J. Wozniak, Christina S. Baik, Alex Mutebi, Pingkuan Zhang, Heather A. Wakelee, Bruce E. Johnson	12
16	Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy 2013 ·Current Medical Research and Opinion ·Keith L. Davis, (unknown), Juliana Meyers, Wenhui Wei	31
17	Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV 2013 ·BMJ Open ·Calvin Cohen, Juliana Meyers, Keith L. Davis	101
18	Spillover adherence effects of fixed-dose combination HIV therapy 2012 ·Patient Preference and Adherence ·Teresa L. Kauf, Keith L. Davis, Stephanie Earnshaw, Elizabeth Davis	21
19	Direct economic burden of high-risk and metastatic melanoma in the elderly 2009 ·Applied Health Economics and Health Policy ·Keith L. Davis, Debanjali Mitra, Srividya Kotapati, Ramy Ibrahim, Jedd D. Wolchok	21
20	Monitoring nortriptyline plasma concentrations 1980 ·American Journal of Psychiatry ·(unknown), Adolf Pfefferbaum, Keith L. Davis	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact